News & events
Highlights of news and activities at Satya
recent posts
Satya announces discovery of best-in-class, selective PKMYT1 inhibitor in collaboration with US/ Japanese biotech Alivexis, Inc.
Satya Pharma and Alivexis have discovered a highly selective, safe and best-in-class PKMYT1 inhibitor for...
Read MoreSatya attending ASCO 2024 in Chicago (May 31st – June 4th, 2024)
Satya is attending ASCO in Chicago with a focus on DDR space. To set up...
Read MoreSatya to present preclinical profile of its PARG inhibitors at the 2024 American Association for Cancer Research (AACR) Annual Meeting – April 5-10, San Diego, CA
Abstract title Preclinical profile of novel and potent small molecule inhibitors of PARG Poster number 7112...
Read MoreAll posts
Satya announces discovery of best-in-class, selective PKMYT1 inhibitor in collaboration with US/ Japanese biotech Alivexis, Inc.
Satya Pharma and Alivexis have discovered a highly selective, safe and best-in-class PKMYT1 inhibitor for...
Read MoreSatya attending ASCO 2024 in Chicago (May 31st – June 4th, 2024)
Satya is attending ASCO in Chicago with a focus on DDR space. To set up...
Read MoreSatya to present preclinical profile of its PARG inhibitors at the 2024 American Association for Cancer Research (AACR) Annual Meeting – April 5-10, San Diego, CA
Abstract title Preclinical profile of novel and potent small molecule inhibitors of PARG Poster number 7112...
Read MoreSatya @ JPM 2024
Satya had meetings with potential partners and collaborators to discuss its portfolio of programs during...
Read MoreSatya to present the preclinical profile of first-in-class RAD51 inhibitors at the Upcoming ESMO Congress – Oct 20-24, Madrid, Spain
Abstract title SAT-122, a potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci...
Read MoreSatya to Highlight its SOS1 inhibitors that demonstrate best-in-class single agent activity in preclinical models of KRAS driven tumors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA
Abstract title Best in class, potent, SOS1 inhibitors demonstrate single agent activity in preclinical...
Read MoreSatya to present preclinical profile of its KIF18A inhibitors at the Upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics – Oct 11-15, Boston, USA
Abstract title Preclinical profile of novel and potent small molecule inhibitors of KIF18A inhibitors...
Read MoreSatya is at BIO, 2023 – Boston, June 3-6
Satya is attending the BIO at Boston during June 3-6, 2023. Please also visit the...
Read More
Satya chosen as one of the top Promising startups at BIO ASIA 2023
BIO ASIA 2023 held in February 2023 Satya is chosen as one of the most...
Read MoreSatya is at JPM 2023
Please set up a meeting with CSN at murthycsn@satyarx.com
Read MoreSatya is at JPM, 2023
Please set up meetings with CSN at murthcsn@satyarx.com
Read More